KAG-308

KAG-308 Suppliers list
Company Name: TargetMol Chemicals Inc.
Tel: +1-781-999-5354; +17819995354
Email: marketing@targetmol.com
Products Intro: Product Name:KAG-308
CAS:1215192-68-9
Purity:98.00% Package:100 mg;500 mg Remarks:REAGENT;FOR LABORATORY USE ONLY
Company Name: Fan De(Beijing) Biotechnology Co., Ltd.  
Tel: 15911056312
Email: liming@bio-fount.com
Products Intro: Product Name:KAG-308
CAS:1215192-68-9
Purity:97.0% Package:5mg
Company Name: Guangzhou Younan Technology Co., Ltd  
Tel: 020-82000279 18988941452
Email: YN_research@163.com
Products Intro: Product Name:KAG-308
CAS:1215192-68-9
Purity:0.98 Package:5mg;10mg;25mg;50mg;100mg
Company Name: cjbscvictory  
Tel: 13348960310 13348960310;
Email: 3003867561@qq.com
Products Intro: Product Name:KAG-308
CAS:1215192-68-9
Purity:98% Package:5mg;10mg;20mg;50mg;100mg;200mg
Company Name: TargetMol Chemicals Inc.  
Tel: 4008200310
Email: marketing@tsbiochem.com
Products Intro: Product Name:KAG-308
CAS:1215192-68-9
Package:100mg/RMB 186900;50mg/RMB 133000;25mg/RMB 94500
KAG-308 Basic information
Product Name:KAG-308
Synonyms:KAG-308;2H-Cyclopenta[b]furan-5-ol, 3,3-difluorohexahydro-4-[(1E,3R,4R)-3-hydroxy-4-(3-methylphenyl)-1-penten-1-yl]-2-[4-(2H-tetrazol-5-yl)butylidene]-, (2Z,3aR,4R,5R,6aS)-;KAG 308,KAG308
CAS:1215192-68-9
MF:C24H30F2N4O3
MW:460.52
EINECS:
Product Categories:
Mol File:1215192-68-9.mol
KAG-308 Structure
KAG-308 Chemical Properties
Boiling point 615.6±65.0 °C(Predicted)
density 1.32±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
solubility Soluble in DMSO
form Solid
pka5.00±0.10(Predicted)
color White to light yellow
Safety Information
MSDS Information
KAG-308 Usage And Synthesis
UsesKAG-308 is a potent selective and orally active agonist of EP4 receptor (a prostaglandin E2 receptor subtype), suppresses colitis and promotes histological mucosal healing, potently inhibits TNF-α production. KAG-308 shows a Ki and an EC50 of 2.57 nM and 17 nM for human EP4 receptor, respectively, more selective over EP1, EP2, EP3 and IP receptor[1].
References[1] Watanabe Y, et al. KAG-308, a newly-identified EP4-selective agonist shows efficacy for treating ulcerative colitis and can bring about lower risk of colorectal carcinogenesis by oral administration. Eur J Pharmacol. 2015 May 5;754:179-89. DOI:10.1016/j.ejphar.2015.02.021
KAG-308 Preparation Products And Raw materials
Tag:KAG-308(1215192-68-9) Related Product Information